Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116786 | 1.00 | AAK1 (0.46) | AAK1PRKCZLCKSCN10AGABRA1 | |
| SCHEMBL15116837 | 0.87 | AAK1 (0.46) | AAK1LCKSCN10AGABRA1GABRG2 | |
| SCHEMBL20468222 | 0.83 | AAK1 (0.43) | AAK1LCKSCN10APDE2A | |
| SCHEMBL20054435 | 0.82 | AAK1 (0.50) | AAK1PRKCZLCKSCN10AGABRA1 | |
| SCHEMBL15116746 | 0.82 | AAK1 (0.50) | AAK1PRKCZLCKSCN10AGABRA1 | |
| SCHEMBL15116751 | 0.81 | AAK1 (0.52) | AAK1PRKCZLCKSCN10AGABRA1 | |
| SCHEMBL17192925 | 0.81 | AAK1 (0.43) | AAK1LCKSCN10AGABRA1GABRG2 | |
| SCHEMBL19388574 | 0.71 | SCN10A (0.35) | AAK1SCN10APDE2A | |
| SCHEMBL15116840 | 0.71 | SCN10A (0.35) | AAK1SCN10APDE2A | |
| SCHEMBL15584671 | 0.70 | CACNA1H (0.53) | AAK1PRKCZLCKGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |